Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02069093 · ClinicalTrials.gov registry record · Phase 2
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT02069093 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 92 participants.
The verdict
NCT02069093, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
Open-label, Phase II study of Stomatitis prevention with a steroid-based mouthwash in Post-menopausal women with ER+, HER2- Metastatic or Locally Advanced Breast Cancer
Interventions
- DRUG Exemestane
- DRUG Everolimus
- DRUG Dexamethasone based mouthwash
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02069093
The ClinicalTrials.gov registry entry for NCT02069093 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Exemestane is the first listed.
NCT02069093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02069093 about?
NCT02069093 is a clinical study titled "Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer". Open-label, Phase II study of Stomatitis prevention with a steroid-based mouthwash in Post-menopausal women with ER+, HER2- Metastatic or Locally Advanced Breast Cancer
What is the current status of trial NCT02069093?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2014-05. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02069093?
The interventions under investigation include: Exemestane (DRUG), Everolimus (DRUG), Dexamethasone based mouthwash (DRUG).
Who is sponsoring clinical trial NCT02069093?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.